The present invention refers to a combination of hyaluronic acid, chondroitin sulfate in combination with at least one antacid agent, in particular magaldrate, for the prevention or treatment of gastric hyperacidity and gastroesophageal reflux and related pathologies thereof. More particularly, the combination is used for the preparation of oral compositions with at least one pharmaceutical carrier and advantageously that comprise a bioadhesive agent as well.
